T1	Participants 70 114	pulmonary arterial hypertension in children.
T2	Participants 340 349	children.
T3	Participants 496 514	children with PAH.
T4	Participants 543 617	29 children treated with inhaled treprostinil for â‰¥6 weeks was performed
T5	Participants 998 1011	in 4 patients
T6	Participants 1684 1716	targeted PAH therapy in children
T7	Participants 1828 1864	warranted in pediatric patients with
